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Introduction
Antithrombin III (ATIII) is a recognized treatment for patients
with congenital ATIII deficiency [1–5] (see also the approval
of this indication by the Food and Drug Administration); in
contrast, the evidence supporting its use for other clinical
indications is uncertain [6–10].
In Italian hospitals this drug is widely used in patients admit-
ted to intensive care units (ICUs), who are generally given
ATIII for the treatment of sepsis or disseminated intravascular
coagulation (DIC). The approval of ATIII by the Italian Ministry
of Health was granted nearly 10 years ago (before the pro-
found reform of the Drug Regulatory Agency made by the
ATIII = antithrombin III; CI = confidence interval; DIC = disseminated intravascular coagulation; ICU, intensive care unit; RCT = randomized con-
trolled trial.
*See Appendix 1
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Introduction The administration of antithrombin III (ATIII) is useful in patients with congenital
deficiency, but evidence for the other therapeutic indications of this drug is still uncertain. In Italy, the
use of ATIII is very common in intensive care units (ICUs). For this reason we undertook an
observational study to determine the pattern of use of ATIII in ICUs and to assess the outcome of
patients given this treatment.
Methods From 20 May to 20 July 2001 all consecutive patients admitted to ICUs in 20 Italian
hospitals and treated with ATIII were enrolled. The following information was recorded from each
patient: congenital deficiency, indication for use of ATIII, daily dose and duration of ATIII treatment,
outcome of hospitalization (alive or dead). The outcome data of our observational study were
compared with those reported in previously published randomized controlled trials (RCTs).
Results Two hundred and sixteen patients were enrolled in the study. The clinical indications for using
ATIII were sepsis (25.9%), disseminated intravascular coagulation (23.1%), and other clinical
conditions (46.8%). At the end of the study, 65.3% of the patients were alive, 24.5% died and 10.2%
were still in the hospital. Among the patients with sepsis (n = 56), 19 died during the observation
period (33.9%; 95% confidence interval 22.1–47.5%).
Discussion Our study described the pattern of use of ATIII in Italian hospitals and provided
information on the outcome of the subgroup treated with sepsis. A meta-analysis of current data from
RCTs, together with our findings, indicates that there is no sound basis for using this drug in ICU
patients with sepsis.
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Italian Ministry of Health in 1993) and has remained unchanged
since then. This approval of ATIII was rather generic and
included ‘congenital deficiency of ATIII and all clinical condi-
tions that can cause an acquired deficiency of ATIII’.
Three small randomized studies [7–9] and one large interna-
tional trial [10] assessed the effectiveness of ATIII in sepsis, but
none of these trials found a significant benefit in terms of
reduced morbidity or mortality. As regards congenital deficiency,
the effectiveness of ATIII is fairly well documented [1–5], but
these patients are rare. The other clinical indications (such as
acute thrombosis or thromboembolism, prevention of DIC in
hepatic coma, and treatment of bleeding episodes in cirrhosis)
are supported by a small series of very preliminary studies (see,
for example, the Drugdex databank, CD-ROM Drugdex, volume
110; Micromedex, Englewood, Colorado, USA).
To achieve a better definition of the current use of ATIII in
Italian hospitals and to generate naturalistic data (based on
routine practice) about the outcome of this treatment, we
undertook a multicenter observational study.
Methods
Design of the study and aims
The study was based on a multicenter observational design.
From 20 May to 20 July 2001 all consecutive patients admit-
ted to ICUs in 20 Italian hospitals and treated with ATIII were
enrolled in the study. The study had the following aims: (1)
surveying the use of ATIII in patients admitted to ICUs; (2)
determining the outcome of patients treated with ATIII; and
(3) comparing the results obtained from our observational
study with those previously found in the randomized con-
trolled trials (RCTs).
A meta-analysis was also conducted to summarize the infor-
mation deriving from four RCTs [7–10] that studied the effec-
tiveness of ATIII in sepsis.
Data collection
The following information was recorded from each patient
enrolled in the study: (1) demographic characteristics (age,
sex, weight); (2) congenital deficiency (y/n); (3) baseline ATIII
level; (4) ward of first admission in the hospital; (5) clinical
indication for using ATIII (sepsis or DIC or any other clinical
condition); (6) daily dose and duration of treatment with ATIII;
(7) outcome of hospitalization (alive or dead); and (8) concur-
rent administration of antibiotics and/or heparin.
Analysis
The information collected from each patient was analyzed by
standard descriptive statistics. In the subgroup of patients
with sepsis, the in-hospital mortality rate observed in our
study was compared with that previously reported by the four
RCTs. All rates were presented together with their 95% con-
fidence interval (CI), which was calculated by using Equa-
tions 1.26 and 1.27 of Fleiss [11].
Results
The overall number of patients who were admitted to ICUs
during the study period was 1648. Of these patients, 216
(13%) were enrolled in our study. The characteristics of these
216 patients are presented in Table 1.
The clinical indication for using ATIII was sepsis (n = 56), DIC
(n = 50), or other (n = 101). Table 1 also reports separate
information for the subgroup of 56 patients treated for sepsis.
The duration of ATIII therapy did not differ at levels of statisti-
cal significance between patients treated for different clinical
indications (P = 0.57 according to an analysis of variance).
The daily dose of ATIII showed a difference between sepsis
and other indications (Table 1).
Table 2 reports the outcome of hospitalization according to
clinical indication. With regard to the use of ATIII in patients
with sepsis, Figure 1 shows the percentage mortality rate
(with 95% CI) observed in our study, together with the rates
found in four previous studies [7–10].
Subgroup analyses within the patient cohort of our study did
not identify any relationship between mortality and patient
characteristics. The administration of heparin, which Warren
et al. [10] found to have some implications for outcome, did
not influence mortality in our patient series: mortality was
19.6% in the 107 patients who received heparin, compared
with 30.5% in the 95 patients who did not receive this drug
(P = 0.10) by Fisher’s exact test; mortality was 28.6% in the
28 patients with sepsis who received heparin, compared with
42.3% in the 26 patients with sepsis who did not receive this
drug (P = 0.39).
Discussion
The main scientific value of our observational and prospective
study lies in its naturalistic design; the population of patients
that we studied was in fact drawn from the everyday practice
of more than 20 hospitals and was intentionally free from spe-
cific exclusion criteria.
In interpreting our outcome data, one disadvantage is that the
group treated with ATIII was not compared with any reference
group observed prospectively within our research; neither did
we include any retrospective control group not treated with
the drug. However, historical retrospective controls would
have raised profound problems of matching the retrospective
data with the prospective ones. A prospective enrollment of
controls not treated with ATIII was not feasible because the
therapeutic policy of the ICUs involved in our study was to
administer ATIII to virtually all patients with a diagnosis of
sepsis or DIC.
Regardless of our statistical indexes, a ‘first-look’ comparison
between the data on sepsis produced by the previous RCTs
(including four treatment groups and four control groups) andthose observed in our naturalistic study indicates a complete
overlap of the various survival rates and of their respective
95% CIs. This qualitative impression (Figure 1) is in agree-
ment with the meta-analysis shown in Figure 2 (see
Appendix 2 for details of its methodology).
This meta-analysis gave the following results: summary
odds ratio 0.98; 95% CI 0.83–1.15, P = 0.80; χ2 for het-
erogeneity 1.86; 3 degrees of freedom; P = 0.60. In this
meta-analysis, the large-scale trial by Warren et al. [10]
outweighed the other three small RCTs in that Warren’s
trial included 93% of the overall cohort of the four RCTs. In
the light of the above data, there seems to be no clinical
benefit in administering ATIII to critical patients with
sepsis; in this context, one crucial point is that the most
recent large-scale trial gave very clear results and was neg-
ative. The other clinical indications reported in our patients’
series were more difficult to interpret because of the nearly
complete lack of previous controlled studies exploring
these therapeutic issues.
There has been a lively debate in the literature on the relative
merits of observational studies and RCTs in providing useful
evidence of clinical effectiveness [12–14]. Although the great
majority of researchers stick to the concept that RCTs are the
gold standard, common sense suggests that having informa-
tion both from RCTs and from observational studies is better
than having information from RCTs only. In this framework,
our study advances knowledge about the use of ATIII in criti-
cal patients.
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Table 1
Characteristics of the 216 patients enrolled in our observational study and of the subgroup of 56 patients treated for sepsis
Overall group of patients Patient subgroup with sepsis
Patients’ characteristics n Characteristics n Characteristics
Age (years) 208 62.0 ± 17.2 52 61.8 ± 16.7
Sex (male, female) 211 146, 65 52 38, 14
Body weight (kg) 162 75.5 ± 9.2 48 77.9 ± 16.2
ATIII level at baseline (%) 209 57.4 ± 18.2 55 54.3 ± 14.9
Congenital deficiency 180 1 (0.5%) 47 0 (0%)
Ward of admission (surgery, other) 204 111, 93 51 27, 24
Administration of antibiotics 199 179 (83%) 53 50 (89%)
Administration of heparin 202 107 (50%) 54 28 (50%)
Daily dose of ATIII (units per patient) 195 1758 ± 1092 47 1988 ± 981
Duration of administration of ATIII (days) 195 3.1 ± 4.1 47 3.5 ± 2.6
n is the number of evaluable patients. Where errors are shown these are SDs. The daily doses of ATIII according to the clinical indications were as
follows: sepsis (n = 47), 1988 ± 981 units/day; disseminated intravascular coagulation (n = 46), 1857 ± 967 units/day; other indications (n = 94),
1518 ± 1000 units/day. A one-way analysis of variance showed that these values were significantly different (F = 4.1; 2 and 184 degrees of
freedom; P = 0.02); post-hoc tests showed that the only difference that reached significance was between sepsis and other indications (P = 0.03).
Table 2
Relationship between clinical indication for the use of ATIII and outcome of hospitalization
Outcome of hospitalization
Clinical indication n Alive Dead Still in hospital at the end of the study
Sepsis 56 31 (55.4%) 19 (33.9%) 6 (10.7%)
DIC 50 30 (60%) 16 (32%) 4 (8%)
Any other clinical condition 101 75 (74.3%) 16 (15.8%) 10 (9.9%)
Not reported 9 5 (55.6%) 2 (22.2%) 2 (22.2%)
Total 216 141 (65.3%) 53 (24.5%) 22 (10.2%)
Percentages, which should be read horizontally, indicate which of the three outcomes was found in the various patient subgroups. 
DIC, disseminated intravascular coagulation.In conclusion, our findings based on an observational
prospective study and on an updated meta-analysis of the
previous RCTs do not support the use of this drug in ICU
patients with sepsis.
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Key messages
• Antithrombin III (ATIII) is a recognized treatment for
patients with congenital ATIII deficiency; in contrast,
the evidence supporting its use for other clinical 
indications is uncertain
• In Italian hospitals this drug is widely used in patients
admitted to intensive care units (ICUs), who are 
generally given ATIII for the treatment of sepsis or 
disseminated intravascular coagulation
• Three small randomized studies and one large 
international trialhave assessed the effectiveness of
ATIII in sepsis, but none of these trials has found a 
significant benefit in terms of reduced morbidity or
mortality
• Our findings, based on an observational prospective
study and on an updated meta-analysis of the previous
randomized controlled trials, do not support the use of
this drug in ICU patients without congenital deficiency
Figure 2
Comparison of death rates between patients given ATIII and patients
given placebo in the four RCTs that met the inclusion criteria of out
meta-analysis. The odds ratios of the individual studies and of our
meta-analysis are denoted by dots and by a diamond, respectively;
each horizontal bar indicates the 95% CI for the odds ratio, and the
vertical dotted line represents the identity line. From top to bottom,
datasets are the trials of Warren et al. [10], Baudo et al. [8], Eisele et
al. [9], and Fourrier et al. [7]; the bottom dataset is our meta-analysis.
In the four RCTs, the crude death rates in the treatment group and in
the control group, respectively, were as follows: Fourrier et al. [7], 7 of
17 versus 9 of 18; Eisele et al. [9], 5 of 20 versus 9 of 22; Baudo et al.
[8], 31 of 50 versus 33 of 48; Warren et al. [10], 450 of 1157 versus
448 of 1157.
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Figure 1
Percentage mortality rate (with 95% CI) of patients with sepsis:
comparison between the results of our observational study and those
reported in the four RCTs previously published. Solid lines, treatment
groups; broken lines, control groups; dates of publication: 1993,
Fourrier et al. [7]; early 1998, Eisele et al. [9]; late 1998, Baudo et al.
[8]; 2001, Warren et al. [10] and our study.
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Appendix 1: Gruppo di Studio
sull’antitrombina III (The Antithrombin Study
Group)
The Antithrombin Study Group includes the study coordina-
tors (A Messori, F Vacca, M Vaiani, S Trippoli, Laboratorio di
Farmacoeconomia, c/o Azienda Ospedaliera Careggi,
Firenze) and a total of 51 participants. The names and
addresses of the participants involved in the project were the
following (all located in Italy): R Banfi, M Cecchi, E Cini, D
Dupuis, T Falai, R Fornaini, A Ipponi, ML Migliaccio, F
Pelagotti, L Rabatti, I Ruffino, R Silvano, E Tendi (Firenze, four
hospitals); P Becagli, M Monciatti (Empoli); B Bozzone, R
Casullo, F Cattel, S Pardossi, R Passera, S Stecca, U Taglia-
ferro (Torino, two hospitals); P Di Bartolomeo, T Faggiano, M
Lattarulo (Bari); N Caboni, A Cannas (Cagliari); A Plescia, M
Sorci (Rimini); L Bonistalli, M Puliti (Prato); B Ciammitti, M
Costantini, F Mammini (Terni); L De Cicco, G Mazzaferro
(Napoli); P Marrone, R Tetamo (Palermo); P Beneduce, MG
Celeste, P Fiorani, S Galeassi, G Guaglianone, A Pecere, L
Ragni (Roma, two hospitals); SM Germinario (Andria); O
Basadonna, L Todesco (Camposampiero, Padova); R Calle-
gari, M Pegoraro (Asolo); E Lamura (Ancona).
Appendix 2: Methodology of the meta-analysis
A MedLine search (PubMed, http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi) was performed to cover the period from
January 1980 to November 2001. The search was limited to
the studies published in English and was based on four index
terms combined with the following Boolean syntax: “antithrom-
bin III” AND (sepsis OR septic shock OR “disseminated
intravascular coagulation”). This search was supplemented by
examining the Drugdex databank (CD-ROM Drugdex, volume
110; Micromedex, Englewood, Colorado, USA).
Eligible studies were included if they met the following criteria:
patients were admitted to an ICU; randomized design; diagno-
sis of sepsis, septic shock or DIC; assessment of survival. The
odds ratio was used as the main index to assess the treatment
effect within each trial and to generate the overall results of
the meta-analysis. The calculation of the summary odds ratios
was based on a random-effect model [15,16]. Heterogeneity
was assessed as described previously [17].
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